Meanwhile, compared with untreated APP/PS1 mice, in APP/PS1 mice treated with the combination of PE and BCI-838 (APP/PS1 combination) for 1 month, 17 DEGs were identified (seven up-regulated, 10 down-regulated), which were enriched for SUZ12, as well as glycogen metabolism and exercise-induced myalgia pathways. The gene discussed is SUZ12; the disease is Myalgia.